Genetico Center (CGRM, MOEX: GECO) has published an analytical review of international markets of next-generation sequencing — NGS.
According to the review, the NGS market will grow at an average compound annual growth rate of 17.17% and reach 35.44B US dollars by 2030. The global NGS data analysis market is expected to reach 13.1B US dollars by 2033.
Next Generation Sequencing (NGS) is a genome sequencing technology. Depending on the end user, the NGS market is divided into scientific and research centers, pharmaceutical and biotech companies, and clinics. The research segment occupied the largest market share in 2023, with oncology having the highest share (28.72%). The clinical trial segment is expected to be the fastest growing segment with an average annual growth of 22.93%.
In clinical practice, NGS-based studies are used for search of the gene-level causes of diseases, diagnosis clarification and forecasting the disease course (especially in complex cases), and selection of efficient therapy.
According to an analytical review by Roscongress, Russia’s share in the global market of custom medical services using DNA sequencing is 1%. The potential size of the genetic research market in Russia in the area of orphan diseases may reach 28.7M US dollars.
Special attention should be paid to the market of NGS technologies for screening possible diseases in future parents in preparation for pregnancy. According to the estimates by specialists of CGRM GENETICO PJSC based on the number of children born and the average market cost of testing as well as the fact that only 3–6% of future parents undergo genetic testing, the total potential market size of NGS testing in the Russian Federation for pregnancy preparation in 2023 may be 102M US dollars. On the other hand, the market size in 2023 (SOM) may be about 9.5M US dollars if we take into account that, according to expert survey data, about 50% of future parents undergoing genetic testing use methods different from NGS and the financial eligibility. The main drivers of future NGS demand in Russia are as follows:
Genetico Center (CGRM, MOEX: GECO) is a part of Artgen Biotech (MOEX: ABIO), Skolkovo resident, Medtech Technopark resident. The company conducts their business in medical genetics and genetic testing and implements the innovative solutions for diagnostics, prevention and treatment of genetic, oncological and other socially significant and orphan diseases into practical healthcare. In 2023, the company launched a new biotechnological activity — development of gene therapy drugs for treatment of orphan diseases. The trials focus on initial stages of candidate drug development for therapy of ophthalmological diseases, hereditary cardiomyopathies and neurodegenerative diseases.
Use the link, to read the full version of the analytical report.